08:21 IST
BSE
Product Launch
Biocon Product Launch
Biocon Limited has commercially launched 'Yesafili', a biosimilar to Eylea, in the United States market. This product strengthens the company's ophthalmology portfolio.
Biocon Ltd
Biocon Ltd news stories on ALFA NewsRead the news →- Share price
- ₹360.70
- Market cap
- ₹58,783 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 118.7×Sector 47.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Regulatory Approval 6Earnings Call 6Annual General Meeting 6Other Announcement 4Capital Structure Change 4Business Update 4New Order Win 3Management Change 3Fund Raise 3Financial Results 3Results Update 2Product Launch 2Merger & Restructuring 2Board Meeting Outcome 2Board Meeting Date 2Acquisition 2Price Movement Clarification 1Dividend 1Annual Report 1
Time
2 announcements with these filters
16:03 IST
BSE
Product Launch
Biocon Product Launch
Biocon Limited has commercially launched Bosaya and Aukelso, its interchangeable denosumab biosimilars, in the United States. These products target the $5 billion U.S. market for osteoporosis and bone metastasis treatments. This strategic expansion strengthens Biocon's global biosimilars portfolio and provides affordable treatment options for over 10 million patients.
- Value
- ₹46,500 Cr